Drug intelligence / Profile preview

DWC202204 + DWC202205

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules

Overview

DWC202204 and DWC202205 are small molecule drugs developed by Daewoong Pharmaceutical Co., Ltd. They are involved in a Phase I clinical trial to evaluate drug-drug interactions with DWP16001 in healthy male adults. The primary focus is on assessing pharmacokinetics, pharmacodynamics, safety, and tolerability. The therapeutic area is metabolic disorders, specifically related to Type 2 Diabetes.

Beyond the preview

Go deeper on DWC202204 + DWC202205.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC202204 + DWC202205.

Explore the full profile